Inotek Pharmaceuticals Corp (ITEK) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $22. H.C. Wainwright advised their investors in a research report released on Sep 20, 2016.
Inotek Pharmaceuticals Corp opened for trading at $8.01 and hit $8.47 on the upside on Friday, eventually ending the session at $8.31, with a gain of 4.01% or 0.32 points. The heightened volatility saw the trading volume jump to 492,568 shares. Company has a market cap of $224 M.
In a different news, on May 17, 2016, J Martin Carroll (director) purchased 10,000 shares at $9.03 per share price.
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company advancing molecules with new mechanisms of action to address diseases of the eye. The Company’s business strategy is to develop and progress its product candidates through human clinical trials. The Company is focused on the discovery development and commercialization of therapies for glaucoma. Its lead product candidate trabodenoson is a selective adenosine mimetic that is designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company’s product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation as well as a fixed dose combination (FDC) of trabodenoson with latanoprost given once-daily (QD).